By the end of the year, Mymetics will publish the results of a Phase 1 clinical trial of its vaccine against the human immunodeficiency virus. An earlier animal study showed that the vaccine, which triggers antibodies in both blood and mucus membranes, provided 100 percent protection. Simplirix
SHARE

MORE TO READ